Close Menu

NEW YORK – Heavily pretreated, refractory multiple myeloma patients have a new treatment option following the US Food and Drug Administration's approval last week of Bristol Myers Squibb and Bluebird Bio's idecabtagene vicleucel (Abecma), the first CAR T-cell therapy approved in this setting.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.